News For WPI From The Last 14 Days Check below for free stories on WPI the last two weeks.
There are 14 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 13, 2012
|
| 07:30 EDT |  | WPI |
| | 06:59 EDT |  | WPI |
|
|
February 10, 2012
|
| 16:09 EDT | | WPI |
| theflyonthewall.com: | Watson Pharmaceuticals confirms Beyaz patent challenge | | Watson Pharmaceuticals (WPI) confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application with the U.S. Food and Drug FDA seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg. Watson's ANDA product is a generic version of Bayer HealthCare Pharmaceuticals' (BAYRY) Beyaz. Beyaz is an oral contraceptive indicated for use by women to prevent pregnancy, treat symptoms of premenstrual dysphoric disorder for women who choose to use an oral contraceptive for contraception, treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control, and raise folate levels in women who choose to use an oral contraceptive for contraception. :theflyonthewall.com |
| | 15:30 EDT |  | WPI |
| | 14:11 EDT | | WPI |
|
|
February 8, 2012
|
| 14:41 EDT | | WPI |
| | 11:34 EDT | | WPI |
| theflyonthewall.com: | Watson reaches settlement with Janssen over generic Ortho Tri-Cyclen LO | | Watson Pharmaceuticals (WPI) announced earlier that its subsidiary, Watson Laboratories, has reached a settlement with Janssen Pharmaceuticals (JNJ) on outstanding patent litigation related to Watson's generic version of Janssen's Ortho Tri-Cyclen LO tablets. As part of the settlement, the parties have entered into a supply agreement whereby Janssen will manufacture and supply Watson with an authorized generic version of Ortho Tri-Cyclen LO. Watson will have the right to market and distribute the authorized generic on December 31, 2015, or earlier under certain circumstances. Other details of the settlement were not disclosed. :theflyonthewall.com |
| | 07:57 EDT | | WPI |
|
|
February 7, 2012
|
| 06:30 EDT | | WPI |
|
|
February 6, 2012
|
| 16:18 EDT | | WPI |
|
|
February 3, 2012
|
| 09:32 EDT | | WPI |
| theflyonthewall.com: | Watson Pharmaceuticals provides update on generic Lidoderm application | | In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm patent challenge, Watson Pharmaceuticals issued the following statement: "Watson's abbreviated new drug application, or ANDA, for a generic version of Lidoderm remains on track. We believe questions related to the site where a biostudy supporting the ANDA was conducted have been addressed to FDA's satisfaction. We continue to work closely with the FDA with the goal of timely approval. Watson has made public comments throughout the year regarding our Lidoderm application, including most recently at our analyst day on Jan. 24, where the company restated our confidence that a tentative approval for generic Lidoderm will be received prior to the 30-month stay expiry on July 15. In order not to affect the pending patent litigation trial, it is our policy not to comment during litigation. Therefore, we will not provide additional comment on details that may arise during the trial." :theflyonthewall.com |
|
|
January 31, 2012
|
| 11:21 EDT |  | WPI |
|
|
January 30, 2012
|
| 09:27 EDT | | WPI |
| | 08:16 EDT | | WPI |
|
|
|
Subscribe for More Information